Mark A. Rubin, MD, Professor, Principal Investigator, and Director of the Department for BioMedical Research (DBMR), University of Bern, Switzerland. Prof. Mark Rubin is a recognized world-renown leader in prostate cancer genomics and pathology, and precision medicine. Dr. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Furthermore, Prof. Rubin has translated many of his genomic discoveries into clinical tests that are currently patented and standardly used in the diagnosis and treatment of prostate cancer. Prof. Rubin founded the Englander Institute for Precision Medicine and, more recently, the Bern Center for Precision Medicine (BCPM).